flurbiprofen has been researched along with Muscular Dystrophy, Duchenne in 2 studies
Flurbiprofen: An anti-inflammatory analgesic and antipyretic of the phenylalkynoic acid series. It has been shown to reduce bone resorption in periodontal disease by inhibiting CARBONIC ANHYDRASE.
flurbiprofen : A monocarboxylic acid that is a 2-fluoro-[1,1'-biphenyl-4-yl] moiety linked to C-2 of propionic acid. A non-steroidal anti-inflammatory, analgesic and antipyretic, it is used as a pre-operative anti-miotic as well as orally for arthritis or dental pain.
Muscular Dystrophy, Duchenne: An X-linked recessive muscle disease caused by an inability to synthesize DYSTROPHIN, which is involved with maintaining the integrity of the sarcolemma. Muscle fibers undergo a process that features degeneration and regeneration. Clinical manifestations include proximal weakness in the first few years of life, pseudohypertrophy, cardiomyopathy (see MYOCARDIAL DISEASES), and an increased incidence of impaired mentation. Becker muscular dystrophy is a closely related condition featuring a later onset of disease (usually adolescence) and a slowly progressive course. (Adams et al., Principles of Neurology, 6th ed, p1415)
| Excerpt | Relevance | Reference |
|---|---|---|
| "In patients with Duchenne muscular dystrophy (DMD) and the standard mdx mouse model of DMD, dystrophin deficiency causes loss of neuronal nitric oxide synthase (nNOSĪ¼) from the sarcolemma, producing functional ischemia when the muscles are exercised." | 1.38 | Treatment with a nitric oxide-donating NSAID alleviates functional muscle ischemia in the mouse model of Duchenne muscular dystrophy. ( De Nardi, C; Monopoli, A; Ongini, E; Thomas, GD; Victor, RG; Ye, J, 2012) |
| "Duchenne muscular dystrophy is a relatively common disease that affects skeletal muscle, leading to progressive paralysis and death." | 1.34 | Nitric oxide release combined with nonsteroidal antiinflammatory activity prevents muscular dystrophy pathology and enhances stem cell therapy. ( Bottinelli, R; Brunelli, S; Clementi, E; Cossu, G; Covarello, D; D'Antona, G; Galvez, BG; Innocenzi, A; Monopoli, A; Ongini, E; Perrotta, C; Sanvito, F; Sciorati, C, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Thomas, GD | 1 |
| Ye, J | 1 |
| De Nardi, C | 1 |
| Monopoli, A | 2 |
| Ongini, E | 2 |
| Victor, RG | 1 |
| Brunelli, S | 1 |
| Sciorati, C | 1 |
| D'Antona, G | 1 |
| Innocenzi, A | 1 |
| Covarello, D | 1 |
| Galvez, BG | 1 |
| Perrotta, C | 1 |
| Sanvito, F | 1 |
| Bottinelli, R | 1 |
| Cossu, G | 1 |
| Clementi, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Renal Ageing-sarcopenia Network: a Combined Genetic, Immunological and Psychological Approach to Dissect Frailty[NCT04630132] | 1,500 participants (Anticipated) | Observational | 2017-03-25 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 other studies available for flurbiprofen and Muscular Dystrophy, Duchenne
| Article | Year |
|---|---|
Treatment with a nitric oxide-donating NSAID alleviates functional muscle ischemia in the mouse model of Duchenne muscular dystrophy.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Biomechanical Phenomena; Disease Models, Animal; F | 2012 |
Nitric oxide release combined with nonsteroidal antiinflammatory activity prevents muscular dystrophy pathology and enhances stem cell therapy.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Combined Modality Therapy; Creatine Kin | 2007 |